An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer

Uzoaru, Ikechukwu; Rubenstein, Marvin; Mirochnik, Yelena; Slobodskoy, Leonid; Shaw, Michael; Guinan, Patrick

doi:10.1002/(sici)1096-9098(199801)67:1<33::aid-jso7>3.0.co;2-n

Cited by 24 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3][4][5][6][7] Some studies have suggested that nuclear p53 accumulation may correlate with poor prognosis after radical prostatectomy, 8,9 external beam radiation, 10 and watchful waiting 11 but these data were not confirmed in other studies. [12][13][14] Perhaps some of these discordances were caused by the relatively small number of patients included in these studies ranging from 24-392 patients. 6,15 Despite the high number of previous studies, the role of p53 alterations in prostate cancer and other malignancies is not clearly defined.…”

mentioning

confidence: 99%

Clinical significance of p53 alterations in surgically treated prostate cancers

et al. 2008

View full text Add to dashboard Cite

Despite the high number of previous studies, the role of p53 alterations in prostate cancer is not clearly defined. To address the role of p53 alterations in prostate cancer biology, a total of 2514 cancers treated by radical prostatectomy were successfully analyzed by immunohistochemistry in a tissue microarray format. Overall a low rate of p53-positive tumors was found (2.5%). A significant underestimation of p53-positive cases was excluded by subsequent large section analyses and direct sequencing of the p53 gene in subsets of our patients. Large section analysis of 23 cases considered negative on the tissue microarray yielded only one weakly p53-positive tumor. Only 4 out of 64 (6.4%) high-grade tumors, that were considered negative for p53 by immunohistochemistry, presented exon 5-8 mutations. These data suggest a high sensitivity of our immunohistochemistry approach and confirm the overall low frequency of p53 alterations in clinically localized prostate cancer. A positive p53 immunostaining was strongly associated with presence of exon 5-8 mutations (Po0.0001), advanced pT-stage (Po0.0001), high Gleason grade (Po0.0001), positive surgical margins (P ¼ 0.03) and early biochemical tumor recurrence (Po0.0001). A higher rate of positive p53 immunostaining was detected in late-stage diseases including metastatic prostate cancer (P ¼ 0.0152) and hormone-refractory tumors (P ¼ 0.0003). Moreover, p53 expression was identified as an independent predictor of biochemical tumor recurrence in the subgroup of low-and intermediate-grade cancers. In summary, the results of this study show that p53 mutations characterize a small biologically aggressive subgroup of prostate cancers with a high risk of progression after prostatectomy. The rate of p53 alterations increases with prostate cancer progression.

show abstract

mentioning

confidence: 99%

Clinical significance of p53 alterations in surgically treated prostate cancers

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The correlation between low Ki-67 index and histologically low-grade tumors is strong [9, 11, 25-35]. Our recent report [36] demonstrated that plasma cKi-67 levels can be used as a biomarker in ALL, and that the only functional difference between the plasma cKi-67 assay and the IHC Ki-67 index assay is that the former lacks normalization to the number of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

Bruey

Kantarjian

et al. 2010

Leukemia Research

View full text Add to dashboard Cite

Ki-67 is a nuclear antigen that is expressed in all stages of the cell cycle, except G0, and is widely used as a marker of cellular proliferation in human tumors. We recently showed that elevated levels of Ki-67 circulating in plasma (cKi-67) are associated with shorter survival in patients with acute lymphoblastic leukemia. The study included 194 patients with CLL and 96 healthy control subjects. cKi-67 levels in plasma were determined using an electrochemiluminescent immunoassay. We normalized the cKi-67 level to the absolute number of lymphocytes in the patient's peripheral blood to establish the plasma cKI-67 index. The cKi-67 index showed significant correlation with lymph node involvement and Rai stage (P = 0.05). Higher cKi-67 index values were significantly associated with shorter survival. Multivariate Cox proportional hazards regression analysis demonstrated that the association of the cKi-67 index with shorter survival was independent of IgVH mutation status. In a multivariate model incorporating the cKi-67 index with B2M and IgVH, only cKi-67 index and B2M levels remained as independent predictors of survival. The results of this study suggest that the plasma cKi-67 index, along with B2M level, is a strong predictor of clinical behavior in CLL

show abstract

“…The p53 gene has been found to be the most important tumor-associated human gene, and the development of human tumors is tightly correlated with its deletion, rearrangement and point mutation [17][18][19][20][21] . p53 allele deletion and point mutation can be detected in many kinds of tumor tissues and 175, 248, 249, 273 and 282 point mutations are very commonly found 22) .…”

Section: Discussionmentioning

confidence: 99%

Detection of Mutant p53 Protein in Workers Occupationally Exposed to Benzidine

Cui-qin

Shen

et al. 2007

Journal of Occupational Health

View full text Add to dashboard Cite

Detection of Mutant p53 Protein inWorkers Occupationally Exposed to Benzidine: Cui-Qin XIANG, et al. Shanghai Municipal Center for Disease Control & Prevention, China-To investigate the expression of mutant p53 protein in workers occupationally exposed to benzidine, we detected mutant p53 protein by immuno-PCR assay in the serum of 331 benzidine-exposed healthy workers, while we classified exfoliated urothelial cells in urine samples with Papanicoloau's grading (PG). The Papanicoloau's grading classified exfoliated urothelial cells of the subjects from grade I (normal cells) to grade III (suspicious malignant cells). The subjects were also divided into high, medium and low exposure groups according to the exposure intensity index. The results revealed that mutant p53 protein in the medium and high exposure groups were significantly higher than the in low exposure group (p<0.05), and in PG II and III were significantly higher than in the PG I (p<0.05). There was no significant differences among Papanicoloau's gradings strata in the low exposure group on the incidence and quantity of mutant p53 protein. In the medium and high exposure groups, the incidence and/or quantity of mutant p53 protein in the stratum of PG II and/or III were significantly higher than that of PG I (p<0.05). Detection of mutant p53 protein in conjunction with benzidine exposure level and Papanicoloau's gradings of exfoliated urothelial cells could provide more information to help us elevate surveillance efficiency and diagnose bladder cancer in the early period. (J Occup Health 2007; 49: 279-284)

show abstract

An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer

Cited by 24 publications

References 22 publications

Clinical significance of p53 alterations in surgically treated prostate cancers

Clinical significance of p53 alterations in surgically treated prostate cancers

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

Detection of Mutant p53 Protein in Workers Occupationally Exposed to Benzidine

Contact Info

Product

Resources

About